Scholars@Duke
Hilliard Foster Seigler

Hilliard Foster Seigler

Professor of Surgery
Surgical Oncology
seigl001@mc.duke.edu
Box 3966 Med Ctr, Durham, NC 27710
Room 469 Seeley Mudd Bldg, Durham, NC 27710

Overview

Our laboratory is involved with tumor immunobiology with special interest in human melanoma. The laboratory is current focusing on the cellular and humoral responses to melanoma tumor cell vaccines. We completed Duke University's first gene therapy program utilizing autologous melanoma cells transduced with the gene for human gamma interferon. The serological and cellular studies indicated that patients made a significant and measurable response to immunization with these gene-modified tumor cells. We immunized 100 patients with autologous dendritic cells pulsed with either autologous tumor lysate or specific melanoma tumor peptides. The cell-mediated immune response to the vaccines was addressed in a serial fashion. At the present time, we are evaluating HLA identical donor stem cells in an effort to produce graft vs. tumor responses in patients with metastatic melanoma.

Current Appointments & Affiliations

Professor of Surgery · 1977 - Present Surgical Oncology, Surgery

Recent Publications

A Historical Cohort in Kidney Transplantation: 55-Year Follow-Up of 72 HLA-Identical, Donor-Recipient Pairs.

Journal Article J Clin Med · November 24, 2021 The impact of HLA matching on graft survival has been well characterized in renal transplantation, with a higher degree of matching associated with superior graft survival. Additionally, living donor grafts are known to confer superior survival compared to ... Full text Link to item Cite

Overall Survival Improved for Contemporary Patients with Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.

Journal Article J Am Coll Surg · April 2014 BACKGROUND: Even after negative sentinel lymph node biopsy (SLNB) for primary melanoma, patients who develop in-transit (IT) melanoma or local recurrences (LR) can have subclinical regional lymph node involvement. STUDY DESIGN: A prospective database ident ... Full text Link to item Cite
View All Publications

Recent Grants

Dendritic Cell Vaccine Against Melanoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 1998

Immunization - Gamma Ifn Transduced Autologous Melanoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 1998

Immunization With Gamma Ifn Transduced Autologous Melanoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1998

View All Grants

Education, Training & Certifications

University of North Carolina, Chapel Hill · 1960 M.D.